Thrivent Financial for Lutherans Trims Stock Holdings in Core Laboratories Inc. (NYSE:CLB)

Thrivent Financial for Lutherans reduced its position in shares of Core Laboratories Inc. (NYSE:CLB) by 3.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,021 shares of the oil and gas company’s stock after selling 1,600 shares during the quarter. Thrivent Financial for Lutherans owned about 0.08% of Core Laboratories worth $792,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Intech Investment Management LLC bought a new stake in Core Laboratories during the 2nd quarter valued at $226,000. Vanguard Personalized Indexing Management LLC boosted its position in Core Laboratories by 15.9% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,907 shares of the oil and gas company’s stock valued at $282,000 after acquiring an additional 1,907 shares in the last quarter. WINTON GROUP Ltd boosted its position in Core Laboratories by 7.4% during the 2nd quarter. WINTON GROUP Ltd now owns 60,010 shares of the oil and gas company’s stock valued at $1,218,000 after acquiring an additional 4,147 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in Core Laboratories by 12.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 306,287 shares of the oil and gas company’s stock valued at $6,215,000 after acquiring an additional 34,149 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in Core Laboratories by 1.4% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 54,310 shares of the oil and gas company’s stock valued at $1,102,000 after acquiring an additional 758 shares in the last quarter. 97.81% of the stock is currently owned by hedge funds and other institutional investors.

Core Laboratories Stock Performance

Shares of CLB stock opened at $20.11 on Tuesday. The firm has a market capitalization of $943.16 million, a price-to-earnings ratio of 22.85, a price-to-earnings-growth ratio of 1.09 and a beta of 2.36. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.39 and a quick ratio of 1.68. The business has a fifty day moving average of $19.20 and a 200 day moving average of $18.84. Core Laboratories Inc. has a 1 year low of $13.82 and a 1 year high of $25.13.

Core Laboratories (NYSE:CLB) last released its quarterly earnings data on Wednesday, July 24th. The oil and gas company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.01. The business had revenue of $130.58 million during the quarter, compared to analyst estimates of $132.85 million. Core Laboratories had a return on equity of 15.20% and a net margin of 5.44%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $0.23 EPS. As a group, research analysts expect that Core Laboratories Inc. will post 0.8 earnings per share for the current year.

Core Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Monday, August 5th were given a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.20%. The ex-dividend date of this dividend was Monday, August 5th. Core Laboratories’s payout ratio is 4.55%.

Analyst Ratings Changes

CLB has been the subject of a number of recent analyst reports. Stifel Nicolaus raised their price objective on Core Laboratories from $18.00 to $22.00 and gave the stock a “hold” rating in a research report on Friday, July 26th. Bank of America lowered their price objective on Core Laboratories from $16.00 to $15.00 and set an “underperform” rating for the company in a research report on Monday, July 15th. StockNews.com cut Core Laboratories from a “hold” rating to a “sell” rating in a research report on Tuesday, September 17th. Finally, Piper Sandler lowered their price objective on Core Laboratories from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Monday, July 15th. Two investment analysts have rated the stock with a sell rating and two have assigned a hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $18.00.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.